Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleBehavioral Pharmacology

Diuretic Effects of Cannabinoids

Carol A. Paronis, Ganesh A. Thakur, Shama Bajaj, Spyros P. Nikas, V. Kiran Vemuri, Alexandros Makriyannis and Jack Bergman
Journal of Pharmacology and Experimental Therapeutics January 2013, 344 (1) 8-14; DOI: https://doi.org/10.1124/jpet.112.199331
Carol A. Paronis
Department of Pharmaceutical Sciences (C.A.P., G.A.T., A.M.) and Center for Drug Discovery (C.A.P., G.A.T., S.B., S.P.N., V.K.V., A.M.), Northeastern University, Boston, and Preclinical Pharmacology Laboratory, McLean Hospital/Harvard Medical School, Belmont, Massachusetts (C.A.P., J.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ganesh A. Thakur
Department of Pharmaceutical Sciences (C.A.P., G.A.T., A.M.) and Center for Drug Discovery (C.A.P., G.A.T., S.B., S.P.N., V.K.V., A.M.), Northeastern University, Boston, and Preclinical Pharmacology Laboratory, McLean Hospital/Harvard Medical School, Belmont, Massachusetts (C.A.P., J.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shama Bajaj
Department of Pharmaceutical Sciences (C.A.P., G.A.T., A.M.) and Center for Drug Discovery (C.A.P., G.A.T., S.B., S.P.N., V.K.V., A.M.), Northeastern University, Boston, and Preclinical Pharmacology Laboratory, McLean Hospital/Harvard Medical School, Belmont, Massachusetts (C.A.P., J.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Spyros P. Nikas
Department of Pharmaceutical Sciences (C.A.P., G.A.T., A.M.) and Center for Drug Discovery (C.A.P., G.A.T., S.B., S.P.N., V.K.V., A.M.), Northeastern University, Boston, and Preclinical Pharmacology Laboratory, McLean Hospital/Harvard Medical School, Belmont, Massachusetts (C.A.P., J.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
V. Kiran Vemuri
Department of Pharmaceutical Sciences (C.A.P., G.A.T., A.M.) and Center for Drug Discovery (C.A.P., G.A.T., S.B., S.P.N., V.K.V., A.M.), Northeastern University, Boston, and Preclinical Pharmacology Laboratory, McLean Hospital/Harvard Medical School, Belmont, Massachusetts (C.A.P., J.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandros Makriyannis
Department of Pharmaceutical Sciences (C.A.P., G.A.T., A.M.) and Center for Drug Discovery (C.A.P., G.A.T., S.B., S.P.N., V.K.V., A.M.), Northeastern University, Boston, and Preclinical Pharmacology Laboratory, McLean Hospital/Harvard Medical School, Belmont, Massachusetts (C.A.P., J.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jack Bergman
Department of Pharmaceutical Sciences (C.A.P., G.A.T., A.M.) and Center for Drug Discovery (C.A.P., G.A.T., S.B., S.P.N., V.K.V., A.M.), Northeastern University, Boston, and Preclinical Pharmacology Laboratory, McLean Hospital/Harvard Medical School, Belmont, Massachusetts (C.A.P., J.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

In vivo effects of cannabinoid (CB) agonists are often assessed using four well-established measures: locomotor activity, hypothermia, cataleptic-like effects, and analgesia. The present studies demonstrate that doses of CB agonists that produce these effects also reliably increase diuresis. Diuretic effects of several CB agonists were measured in female rats over 2 hours immediately after drug injection, and results were compared with hypothermic effects. Direct-acting CB1 agonists, including Δ9-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED50 values for diuresis than for hypothermia. The highest doses of cannabinoid drugs yielded, on average, 26–32 g/kg urine; comparable effects were obtained with 10 mg/kg furosemide and 3.0 mg/kg trans-(-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide (U50-488). Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the CB2 agonist AM1241 [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects. In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)]. These data indicate that cannabinoids have robust diuretic effects in rats that are mediated via CB1 receptor mechanisms.

Footnotes

  • This work was supported in part by the National Institutes of Health National Institute on Drug Abuse [Grants DA19205 and DA26795].

  • dx.doi.org/10.1124/jpet.112.199331.

  • Portions of this work were previously presented at the following conference: Paronis CA, Martin J, Bergman J, Thakur G, Zvonok A, Makriyannis A (2007) Diuretic effects of cannabinoid agonists. European Behavioural Pharmacology Society Meeting; September 2007; Tübingen, Germany.

  • Received August 15, 2012.
  • Accepted September 25, 2012.
  • Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 344 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 344, Issue 1
1 Jan 2013
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Diuretic Effects of Cannabinoids
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleBehavioral Pharmacology

Cannabinoid Diuresis

Carol A. Paronis, Ganesh A. Thakur, Shama Bajaj, Spyros P. Nikas, V. Kiran Vemuri, Alexandros Makriyannis and Jack Bergman
Journal of Pharmacology and Experimental Therapeutics January 1, 2013, 344 (1) 8-14; DOI: https://doi.org/10.1124/jpet.112.199331

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleBehavioral Pharmacology

Cannabinoid Diuresis

Carol A. Paronis, Ganesh A. Thakur, Shama Bajaj, Spyros P. Nikas, V. Kiran Vemuri, Alexandros Makriyannis and Jack Bergman
Journal of Pharmacology and Experimental Therapeutics January 1, 2013, 344 (1) 8-14; DOI: https://doi.org/10.1124/jpet.112.199331
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Behavioral Battery for Testing Candidate Analgesics in Mice
  • Behavioral Battery for Testing Candidate Analgesics II
  • Pharmacology of Mitragynine at μ-Opioid Receptors
Show more Behavioral Pharmacology

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics